Synthetic biology of modular endolysins

Biotechnology Advances

Volumn 36, Issue 3, 2018, Pages 624-640

  Gerstmans, Hans ^a,b   Criel, Bjorn ^a   Briers, Yves ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

clinical trials; Domain swapping; Endolysin; Engineering; Enzybiotics; Fusions; Mutagenesis; Truncation

Indexed keywords

BIOTECHNOLOGY; ENGINEERING; FUSION REACTIONS; MUTAGENESIS;

CLINICAL TRIAL; DOMAIN SWAPPING; ENDOLYSIN; ENZYBIOTICS; TRUNCATION;

BACTERIA;

ANTIMICROBIAL ACTIVITY; BACTERIUM; DRUG RESISTANCE; ENZYME ACTIVITY; GENETIC ENGINEERING; MUTAGENICITY; PATHOGEN; PROTEIN; SPECTRUM;

NEGIBACTERIA; POSIBACTERIA;

ANTIINFECTIVE AGENT; ENDOLYSIN; PROTEINASE; RECOMBINANT PROTEIN;

CELL WALL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HALF LIFE TIME; HUMAN; METABOLISM; MUTAGENESIS; PROCEDURES; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; SYNTHETIC BIOLOGY;

ANTI-BACTERIAL AGENTS; CELL WALL; CLINICAL TRIALS AS TOPIC; ENDOPEPTIDASES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; HUMANS; MUTAGENESIS; PROTEIN DOMAINS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SYNTHETIC BIOLOGY;

EID: 85040007747     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2017.12.009     Document Type: Review

References (182)

1. Abouhmad, A., Mamo, G., Dishisha, T., Amin, M.A., Hatti-Kaul, R., T4 lysozyme fused with cellulose-binding module for antimicrobial cellulosic wound dressing materials. J. Appl. Microbiol. 121 (2016), 115–125, 10.1111/jam.13146.
2. Abouhmad, A., Dishisha, T., Amin, M.A., Hatti-Kaul, R., Immobilization to positively charged cellulose nanocrystals enhances the antibacterial activity and stability of hen egg white and T4 lysozyme. Biomacromolecules 18 (2017), 1600–1608, 10.1021/acs.biomac.7b00219.
3. Arroll, B., Common cold. BMJ Clin. Evid., 2011, 2011.
4. Bai, J., Kim, Y.-T., Ryu, S., Lee, J.-H., Biocontrol and rapid detection of food-borne pathogens using bacteriophages and endolysins. Front. Microbiol., 7, 2016, 474, 10.3389/fmicb.2016.00474.
5. Bastos, M. do C. de F., Coutinho, B.G., Coelho, M.L.V., Lysostaphin: a staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals (Basel) 3 (2010), 1139–1161, 10.3390/ph3041139.
6. Bean, J.E., Alves, D.R., Laabei, M., Esteban, P.P., Thet, N.T., Enright, M.C., Jenkins, A.T.A., Triggered release of bacteriophage K from agarose/hyaluronan hydrogel matrixes by Staphylococcus aureus virulence factors. Chem. Mater. 26 (2014), 7201–7208, 10.1021/cm503974g.
7. Becker, S.C., Foster-Frey, J., Donovan, D.M., The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol. Lett. 287 (2008), 185–191, 10.1111/j.1574-6968.2008.01308.x.
8. Becker, S.C., Foster-Frey, J., Stodola, A.J., Anacker, D., Donovan, D.M., Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443 (2009), 32–41, 10.1016/j.gene.2009.04.023.
9. Becker, S.C., Roach, D.R., Chauhan, V.S., Shen, Y., Foster-Frey, J., Powell, A.M., Bauchan, G., Lease, R.A., Mohammadi, H., Harty, W.J., Simmons, C., Schmelcher, M., Camp, M., Dong, S., Baker, J.R., Sheen, T.R., Doran, K.S., Pritchard, D.G., Almeida, R.A., Nelson, D.C., Marriott, I., Lee, J.C., Donovan, D.M., Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci. Rep., 6, 2016, 25063, 10.1038/srep25063.
10. Blázquez, B., Fresco-Taboada, A., Iglesias-Bexiga, M., Menéndez, M., García, P., PL3 amidase, a tailor-made lysin constructed by domain shuffling with potent killing activity against pneumococci and related species. Front. Microbiol., 7, 2016, 1156, 10.3389/fmicb.2016.01156.
11. Briers, Y., Lavigne, R., Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol 10 (2015), 377–390, 10.2217/fmb.15.8.
12. Briers, Y., Volckaert, G., Cornelissen, A., Lagaert, S., Michiels, C.W., Hertveldt, K., Lavigne, R., Muralytic activity and modular structure of the endolysins of Pseudomonas Aeruginosa bacteriophages phiKZ and EL. Mol. Microbiol. 65 (2007), 1334–1344, 10.1111/j.1365-2958.2007.05870.x.
13. Briers, Y., Cornelissen, A., Aertsen, A., Hertveldt, K., Michiels, C.W., Volckaert, G., Lavigne, R., Analysis of outer membrane permeability of Pseudomonas aeruginosa and bactericidal activity of endolysins KZ144 and EL188 under high hydrostatic pressure. FEMS Microbiol. Lett. 280 (2008), 113–119, 10.1111/j.1574-6968.2007.01051.x.
14. Briers, Y., Schmelcher, M., Loessner, M.J., Hendrix, J., Engelborghs, Y., Volckaert, G., Lavigne, R., The high-affinity peptidoglycan binding domain of Pseudomonas phage endolysin KZ144. Biochem. Biophys. Res. Commun. 383 (2009), 187–191, 10.1016/j.bbrc.2009.03.161.
15. Briers, Y., Walmagh, M., Grymonprez, B., Biebl, M., Pirnay, J.-P., Defraine, V., Michiels, J., Cenens, W., Aertsen, A., Miller, S., Lavigne, R., Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58 (2014), 3774–3784, 10.1128/AAC.02668-14.
16. Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., Oliveira, H., Azeredo, J., Verween, G., Pirnay, J.-P., Miller, S., Volckaert, G., Lavigne, R., Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens. MBio, 5, 2014 e01379-14-e01379-14 https://doi.org/10.1128/mBio.01379-14.
17. Cassino, C., Murphy, M.G., Boyle, J., Rotolo, J., Wittekind, M., Results of the First In Human Study of Lysin CF-301 Evaluating the Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers. 2016 ([WWW Document]. 26th ECCMID, April 9).
18. Chang, Y., Yoon, H., Kang, D.-H., Chang, P.-S., Ryu, S., Endolysin LysSA97 is synergistic with carvacrol in controlling Staphylococcus aureus in foods. Int. J. Food Microbiol. 244 (2017), 19–26, 10.1016/j.ijfoodmicro.2016.12.007.
19. Channabasappa, S., Chikkamadaiah, R., Durgaiah, M., Hariharan, S., Joshi, A., Kumar, S., Maheshwari, U., Nandish, P., Sriram, B., Vijayan, A., Keelara, S., Preclinical Studies of Anti-Staphylococcal Ectolysin P128 for Potential Systemic Hypersensitivity and Evaluation of Efficacy in Staphylococcus aureus Bacteremia with Renal Abscesses in Rats. WWW Document, 2017, ASM Microbe (June).
20. Cheng, Q., Fischetti, V.A., Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. Appl. Microbiol. Biotechnol. 74 (2007), 1284–1291, 10.1007/s00253-006-0771-1.
21. Climo, M.W., Patron, R.L., Goldstein, B.P., Archer, G.L., Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42 (1998), 1355–1360.
22. Climo, M.W., Ehlert, K., Archer, G.L., Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45 (2001), 1431–1437, 10.1128/AAC.45.5.1431-1437.2001.
23. Croux, C., Ronda, C., López, R., García, J.L., Interchange of functional domains switches enzyme specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme. Mol. Microbiol. 9 (1993), 1019–1025.
24. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A., Foster, S., Gilmore, B.F., Hancock, R.E.W., Harper, D., Henderson, I.R., Hilpert, K., Jones, B.V., Kadioglu, A., Knowles, D., Ólafsdóttir, S., Payne, D., Projan, S., Shaunak, S., Silverman, J., Thomas, C.M., Trust, T.J., Warn, P., Rex, J.H., Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect. Dis. 16 (2016), 239–251, 10.1016/S1473-3099(15)00466-1.
25. Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K.J., Fischetti, V.A., Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54 (2010), 1603–1612, 10.1128/AAC.01625-09.
26. Defraine, V., Schuermans, J., Grymonprez, B., Govers, S.K., Aertsen, A., Fauvart, M., Michiels, J., Lavigne, R., Briers, Y., Efficacy of artilysin art-175 against resistant and persistent acinetobacter baumannii. Antimicrob. Agents Chemother. 60 (2016), 3480–3488, 10.1128/AAC.00285-16.
27. DeHart, H.P., Heath, H.E., Heath, L.S., LeBlanc, P.A., Sloan, G.L., The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl. Environ. Microbiol. 61 (1995), 1475–1479.
28. Díaz, E., López, R., García, J.L., Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 8125–8129.
29. Díaz, E., López, R., García, J.L., Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits. J. Biol. Chem. 266 (1991), 5464–5471.
30. Díez-Martínez, R., de Paz, H.D., de Paz, H., Bustamante, N., García, E., Menéndez, M., García, P., Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob. Agents Chemother. 57 (2013), 5355–5365, 10.1128/AAC.01372-13.
31. Díez-Martínez, R., De Paz, H.D., García-Fernández, E., Bustamante, N., Euler, C.W., Fischetti, V.A., Menendez, M., García, P., A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J. Antimicrob. Chemother. 282 (2015), 24990–24999, 10.1093/jac/dkv038.
32. Djurkovic, S., Loeffler, J.M., Fischetti, V.A., Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob. Agents Chemother. 49 (2005), 1225–1228, 10.1128/AAC.49.3.1225-1228.2005.
33. Doehn, J.M., Fischer, K., Reppe, K., Gutbier, B., Tschernig, T., Hocke, A.C., Fischetti, V.A., Loffler, J., Suttorp, N., Hippenstiel, S., Witzenrath, M., Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J. Antimicrob. Chemother. 68 (2013), 2111–2117, 10.1093/jac/dkt131.
34. Dong, Q., Wang, J., Yang, H., Wei, C., Yu, J., Zhang, Y., Huang, Y., Zhang, X.-E., Wei, H., Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococci. Microb. Biotechnol. 8 (2015), 210–220, 10.1111/1751-7915.12166.
35. Drilling, A.J., Cooksley, C., Chan, C., Wormald, P.-J., Vreugde, S., Fighting sinus-derived Staphylococcus Aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme. Int. Forum Allergy Rhinol. 6 (2016), 349–355, 10.1002/alr.21680.
36. Entenza, J.M., Loeffler, J.M., Grandgirard, D., Fischetti, V.A., Moreillon, P., Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49 (2005), 4789–4792, 10.1128/AAC.49.11.4789-4792.2005.
37. Fair, R.J., Tor, Y., Antibiotics and bacterial resistance in the 21st century. Perspect. Medicin. Chem. 6 (2014), 25–64, 10.4137/PMC.S14459.
38. Fenton, M., Casey, P.G., Hill, C., Gahan, C.G., Ross, R.P., McAuliffe, O., O'Mahony, J., Maher, F., Coffey, A., The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng. Bugs 1 (2010), 404–407, 10.4161/bbug.1.6.13422.
39. Fernandes, S., Proença, D., Cantante, C., Silva, F.A., Leandro, C., Lourenço, S., Milheiriço, C., de Lencastre, H., Cavaco-Silva, P., Pimentel, M., São-José, C., Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb. Drug Resist. 18 (2012), 333–343, 10.1089/mdr.2012.0025.
40. Fernández, L., González, S., Campelo, A.B., Martínez, B., Rodríguez, A., García, P., Downregulation of autolysin-encoding genes by phage-derived lytic proteins inhibits biofilm formation in Staphylococcus aureus. Antimicrob. Agents Chemother., 61, 2017, e02724-16, 10.1128/AAC.02724-16.
41. Filatova, L.Y., Donovan, D.M., Becker, S.C., Lebedev, D.N., Priyma, A.D., Koudriachova, H.V., Kabanov, A.V., Klyachko, N.L., Physicochemical characterization of the staphylolytic LysK enzyme in complexes with polycationic polymers as a potent antimicrobial. Biochimie 95 (2013), 1689–1696, 10.1016/j.biochi.2013.04.013.
42. Filatova, L.Y., Donovan, D.M., Ishnazarova, N.T., Foster-Frey, J.A., Becker, S.C., Pugachev, V.G., Balabushevich, N.G., Dmitrieva, N.F., Klyachko, N.L., A chimeric LysK-lysostaphin fusion enzyme lysing Staphylococcus aureus cells: a study of both kinetics of inactivation and specifics of interaction with anionic polymers. Appl. Biochem. Biotechnol. 180 (2016), 544–557, 10.1007/s12010-016-2115-7.
43. Fischetti, V.A., Novel method to control pathogenic bacteria on human mucous membranes. Ann. N. Y. Acad. Sci. 987 (2003), 207–214, 10.1111/j.1749-6632.2003.tb06050.x.
44. Fischetti, V.A., Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13 (2005), 491–496, 10.1016/j.tim.2005.08.007.
45. Fischetti, V.A., Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300 (2010), 357–362, 10.1016/j.ijmm.2010.04.002.
46. Gervasi, T., Horn, N., Wegmann, U., Dugo, G., Narbad, A., Mayer, M.J., Expression and delivery of an endolysin to combat Clostridium perfringens. Appl. Microbiol. Biotechnol. 98 (2014), 2495–2505, 10.1007/s00253-013-5128-y.
47. Gervasi, T., Lo Curto, R., Minniti, E., Narbad, A., Mayer, M.J., Application of Lactobacillus johnsonii expressing phage endolysin for control of Clostridium perfringens. Lett. Appl. Microbiol. 59 (2014), 355–361, 10.1111/lam.12298.
48. Ghahramani, P., Khariton, T., Jones, S., Murphy, J., Boyle, G., Jandourek, A., Cassino, C., Population pharmacokinetic-pharmacodynamic assessment of cardiac safety endpoints for CF-301, a first-in-class antibacterial lysin. WWW Document ASM Microbe, 2017 (June 3) https://www.contrafect.com/news/posters-and-presentations.
49. Gilmer, D.B., Schmitz, J.E., Euler, C.W., Fischetti, V.A., Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57 (2013), 2743–2750, 10.1128/AAC.02526-12.
50. Grandgirard, D., Loeffler, J.M., Fischetti, V.A., Leib, S.L., Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J. Infect. Dis. 197 (2008), 1519–1522, 10.1086/587942.
51. Grundling, A., Missiakas, D.M., Schneewind, O., Staphylococcus aureus mutants with increased lysostaphin resistance. J. Bacteriol. 188 (2006), 6286–6297, 10.1128/JB.00457-06.
52. Gu, J., Xu, W., Lei, L., Huang, J., Feng, X., Sun, C., Du, C., Zuo, J., Li, Y., Du, T., Li, L., Han, W., LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 49 (2011), 111–117, 10.1128/JCM.01144-10.
53. Guo, M., Feng, C., Ren, J., Zhuang, X., Zhang, Y., Zhu, Y., Dong, K., He, P., Guo, X., Qin, J., A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa. Front. Microbiol., 8, 2017, 293, 10.3389/fmicb.2017.00293.
54. Gutiérrez, D., Ruas-Madiedo, P., Martínez, B., Rodríguez, A., García, P., Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One, 9, 2014, e107307, 10.1371/journal.pone.0107307.
55. Haddad Kashani, H., Fahimi, H., Dasteh Goli, Y., Moniri, R., A novel chimeric endolysin with antibacterial activity against methicillin-resistant Staphylococcus aureus. Front. Cell. Infect. Microbiol., 7, 2017, 290, 10.3389/fcimb.2017.00290.
56. Hagens, S., Loessner, M.J., Application of bacteriophages for detection and control of foodborne pathogens. Appl. Microbiol. Biotechnol. 76 (2007), 513–519, 10.1007/s00253-007-1031-8.
57. Hathaway, H., Ajuebor, J., Stephens, L., Coffey, A., Potter, U., Sutton, J.M., Jenkins, A.T.A., Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA). J. Control. Release 245 (2017), 108–115, 10.1016/j.jconrel.2016.11.030.
58. Hathaway, H., Milo, S., Sutton, J.M., Jenkins, T.A., Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins. Ther. Deliv. 8 (2017), 543–556, 10.4155/tde-2017-0040.
59. Hendrix, R.W., Smith, M.C.M., Burns, R.N., Ford, M.E., Hatfull, G.F., Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage. Evolution (N. Y). 96 (1999), 2192–2197.
60. Heselpoth, R.D., Nelson, D.C., A new screening method for the directed evolution of thermostable bacteriolytic enzymes. J. Vis. Exp., 2012, 10.3791/4216.
61. Heselpoth, R.D., Yin, Y., Moult, J., Nelson, D.C., Increasing the stability of the bacteriophage endolysin PlyC using rationale-based FoldX computational modeling. Protein Eng. Des. Sel. 28 (2015), 85–92, 10.1093/protein/gzv004.
62. Horgan, M., O'Flynn, G., Garry, J., Cooney, J., Coffey, A., Fitzgerald, G.F., Ross, R.P., McAuliffe, O., Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl. Environ. Microbiol. 75 (2009), 872–874, 10.1128/AEM.01831-08.
63. Huang, G., Shen, X., Gong, Y., Dong, Z., Zhao, X., Shen, W., Wang, J., Hu, F., Peng, Y., Antibacterial properties of Acinetobacter baumanniiphage Abp1 endolysin (PlyAB1). BMC Infect. Dis., 14, 2014, 681, 10.1186/s12879-014-0681-2.
64. Jado, I., López, R., García, E., Fenoll, A., Casal, J., García, P., Network, Spanish Pneumococcal Infection Study, Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52 (2003), 967–973, 10.1093/jac/dkg485.
65. Jagielska, E., Chojnacka, O., Sabała, I., LytM fusion with SH3b-like domain expands its activity to physiological conditions. Microb. Drug Resist. 22 (2016), 461–469, 10.1089/mdr.2016.0053.
66. Jandourek, A., Boyle, J., Cassino, C., Wittekind, M., Kirby, H., Long term immunology results of a phase 1 placebo controlled dose escalating study to examine the safety of CF-301 in human volunteers [WWW document]. 27th ECCMID, April 22, 2017.
67. Jandourek, A., Boyle, J., Murphy, G., Cassino, C., Inflammatory markers in a phase 1 placebo controlled dose escalating study of intravenous doses of CF-301 in human subjects [WWW document]. ASM Microbe, June 2, 2017.
68. Jayaraman, P., Holowko, M.B., Yeoh, J.W., Lim, S., Poh, C.L., Repurposing a two-component system-based biosensor for the killing of Vibrio cholerae. ACS Synth. Biol. 6 (2017), 1403–1415, 10.1021/acssynbio.7b00058.
69. Johnson, J.W., Fisher, J.F., Mobashery, S., Bacterial cell-wall recycling. Ann. N. Y. Acad. Sci. 1277 (2013), 54–75, 10.1111/j.1749-6632.2012.06813.x.
70. Jun, S.Y., Jung, G.M., Son, J.-S., Yoon, S.J., Choi, Y.-J., Kang, S.H., Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob. Agents Chemother. 55 (2011), 1764–1767, 10.1128/AAC.01097-10.
71. Jun, S.Y., Jung, G.M., Yoon, S.J., Oh, M.-D., Choi, Y.-J., Lee, W.J., Kong, J.-C., Seol, J.G., Kang, S.H., Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int. J. Antimicrob. Agents 41 (2013), 156–161, 10.1016/j.ijantimicag.2012.10.011.
72. Jun, S.Y., Jung, G.M., Yoon, S.J., Choi, Y.-J., Koh, W.S., Moon, K.S., Kang, S.H., Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob. Agents Chemother. 58 (2014), 2084–2088, 10.1128/AAC.02232-13.
73. Jun, S.Y., Jung, G.M., Yoon, S.J., Youm, S.Y., Han, H.-Y., Lee, J.-H., Kang, S.H., Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period. Clin. Exp. Pharmacol. Physiol. 43 (2016), 1013–1016, 10.1111/1440-1681.12613.
74. Jun, S.Y., Jang, I.J., Yoon, S., Jang, K., Yu, K.-S., Cho, J.Y., Seong, M.-W., Jung, G.M., Yoon, S.J., Kang, S.H., Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob. Agents Chemother., 61, 2017, e02629-16, 10.1128/AAC.02629-16.
75. Junjappa, R.P., Desai, S.N., Roy, P., Narasimhaswamy, N., Raj, J.R.M., Durgaiah, M., Vipra, A., Bhat, U.R., Satyanarayana, S.K., Shankara, N., Basingi, S.M., Bhat, J.J., Hariharan, S., Sriram, B., Padmanabhan, S., Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. Vet. Res. Commun. 37 (2013), 217–228, 10.1007/s11259-013-9565-y.
76. Kong, M., Ryu, S., Bacteriophage PBC1 and its endolysin as an antimicrobial agent against Bacillus cereus. Appl. Environ. Microbiol. 81 (2015), 2274–2283, 10.1128/AEM.03485-14.
77. Kong, M., Sim, J., Kang, T., Nguyen, H.H., Park, H.K., Chung, B.H., Ryu, S., A novel and highly specific phage endolysin cell wall binding domain for detection of Bacillus cereus. Eur. Biophys. J. 44 (2015), 437–446, 10.1007/s00249-015-1044-7.
78. Kong, M., Shin, J.H., Heu, S., Park, J.-K., Ryu, S., Lateral flow assay-based bacterial detection using engineered cell wall binding domains of a phage endolysin. Biosens. Bioelectron. 96 (2017), 173–177, 10.1016/j.bios.2017.05.010.
79. Kretzer, J.W., Lehmann, R., Schmelcher, M., Banz, M., Kim, K.-P., Korn, C., Loessner, M.J., Use of high-affinity cell wall-binding domains of bacteriophage endolysins for immobilization and separation of bacterial cells. Appl. Environ. Microbiol. 73 (2007), 1992–2000, 10.1128/AEM.02402-06.
80. Kusuma, C., Jadanova, A., Chanturiya, T., Kokai-Kun, J.F., Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob. Agents Chemother. 51 (2007), 475–482, 10.1128/AAC.00786-06.
81. Lai, M.-J., Lin, N.-T., Hu, A., Soo, P.-C., Chen, L.-K., Chen, L.-H., Chang, K.-C., Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria. Appl. Microbiol. Biotechnol. 90 (2011), 529–539, 10.1007/s00253-011-3104-y.
82. Lai, M.-J., Soo, P.-C., Lin, N.-T., Hu, A., Chen, Y.-J., Chen, L.-K., Chang, K.-C., Identification and characterisation of the putative phage-related endolysins through full genome sequence analysis in Acinetobacter baumannii ATCC 17978. Int. J. Antimicrob. Agents 42 (2013), 141–148, 10.1016/j.ijantimicag.2013.04.022.
83. Lim, J.-A., Shin, H., Heu, S., Ryu, S., Exogenous lytic activity of SPN9CC endolysin against gram-negative bacteria. J. Microbiol. Biotechnol. 24 (2014), 803–811, 10.4014/jmb.1403.03035.
84. Liu, S., Takala, T.M., Wan, X., Reunanen, J., Saris, P.E.J., Cell-mediated killing of Listeria monocytogenes by leucocin C producing Escherichia coli. Microbiol. Res. 168 (2013), 300–304, 10.1016/j.micres.2012.11.011.
85. Liu, S., Takala, T.M., Reunanen, J., Saris, O., Saris, P.E.J., Attachment of Escherichia coli to Listeria monocytogenes for Pediocin-Mediated Killing. Curr. Microbiol. 70 (2015), 195–198, 10.1007/s00284-014-0703-8.
86. Loeffler, J.M., Fischetti, V.A., Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob. Agents Chemother. 47 (2003), 375–377.
87. Loeffler, J.M., Nelson, D., Fischetti, V.A., Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science, 80, 2001, 294.
88. Loeffler, J.M., Djurkovic, S., Fischetti, V.A., Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 71 (2003), 6199–6204.
89. Loessner, M.J., Kramer, K., Ebel, F., Scherer, S., C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol. Microbiol. 44 (2002), 335–349.
90. Lood, R., Raz, A., Molina, H., Euler, C.W., Fischetti, V.A., A highly active and negatively charged streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob. Agents Chemother. 58 (2014), 3073–3084, 10.1128/AAC.00115-14.
91. Lood, R., Winer, B.Y., Pelzek, A.J., Díez-Martínez, R., Thandar, M., Euler, C.W., Schuch, R., Fischetti, V.A., Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob. Agents Chemother. 59 (2015), 1983–1991, 10.1128/AAC.04641-14.
92. Low, L.Y., Yang, C., Perego, M., Osterman, A., Liddington, R., Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins. J. Biol. Chem. 286 (2011), 34391–34403, 10.1074/jbc.M111.244160.
93. Luepke, K.H., Suda, K.J., Boucher, H., Russo, R.L., Bonney, M.W., Hunt, T.D., Mohr, J.F., Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacother. J. Hum. Pharmacol. Drug Ther. 37 (2017), 71–84, 10.1002/phar.1868.
94. Lukacik, P., Barnard, T.J., Buchanan, S.K., Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis. Biochem. Soc. Trans., 40(6), 2012, 1503, 10.1042/BST20120209.
95. Lukacik, P., Barnard, T.J., Keller, P.W., Chaturvedi, K.S., Seddiki, N., Fairman, J.W., Noinaj, N., Kirby, T.L., Henderson, J.P., Steven, A.C., Hinnebusch, B.J., Buchanan, S.K., Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc. Natl. Acad. Sci. 109 (2012), 9857–9862, 10.1073/pnas.1203472109.
96. Lysando, Topical Applications - LYSANDO AG [WWW Document]. 2017.
97. Ma, Q., Guo, Z., Gao, C., Zhu, R., Wang, S., Yu, L., Qin, W., Xia, X., Gu, J., Yan, G., Lei, L., Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus. Antonie Van Leeuwenhoek 110 (2017), 347–355, 10.1007/s10482-016-0806-2.
98. MacKenzie, F.M., Gould, I.M., The post-antibiotic effect. J. Antimicrob. Chemother. 32 (1993), 519–537.
99. Manoharadas, S., Witte, A., Bläsi, U., Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol. 139 (2009), 118–123, 10.1016/j.jbiotec.2008.09.003.
100. Mao, J., Schmelcher, M., Harty, W.J., Foster-Frey, J., Donovan, D.M., Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol. Lett. 342 (2013), 30–36, 10.1111/1574-6968.12104.
101. Mayer, M.J., Garefalaki, V., Spoerl, R., Narbad, A., Meijers, R., Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J. Bacteriol. 193 (2011), 5477–5486, 10.1128/JB.00439-11.
102. Mura, S., Nicolas, J., Couvreur, P., Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12 (2013), 991–1003, 10.1038/nmat3776.
103. Nair, S., Desai, S., Poonacha, N., Vipra, A., Sharma, U., Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob. Agents Chemother. 60 (2016), 7280–7289, 10.1128/AAC.01118-16.
104. Nau, R., Eiffert, H., Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin. Microbiol. Rev. 15 (2002), 95–110, 10.1128/CMR.15.1.95-110.2002.
105. Neill, J.O., Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations The Review on Antimicrobial Resistance Chaired. 2014.
106. Nelson, D., Loomis, L., Fischetti, V.A., Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 4107–4112, 10.1073/pnas.061038398.
107. Nelson, D.C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D.G., Dong, S., Donovan, D.M., Endolysins as Antimicrobials. 2012, 10.1016/B978-0-12-394438-2.00007-4.
108. Oechslin, F., Daraspe, J., Giddey, M., Moreillon, P., Resch, G., In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrob. Agents Chemother. 57 (2013), 6276–6283, 10.1128/AAC.01701-13.
109. Oh, J., Schuch, R., 2017. The Sub-MIC Effect of Lysin CF-301 on Staphylococcus aureus (S. aureus) [WWW Document]. ASM Microbe, June 2.
110. Oliveira, H., Melo, L.D.R., Santos, S.B., Nóbrega, F.L., Ferreira, E.C., Cerca, N., Azeredo, J., Kluskens, L.D., Molecular aspects and comparative genomics of bacteriophage endolysins. J. Virol. 87 (2013), 4558–4570, 10.1128/JVI.03277-12.
111. Oliveira, H., Pinto, G., Oliveira, A., Oliveira, C., Faustino, M.A., Briers, Y., Domingues, L., Azeredo, J., Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. Appl. Microbiol. Biotechnol. 100 (2016), 10543–10553, 10.1007/s00253-016-7858-0.
112. Oliveira, H., Vilas Boas, D., Mesnage, S., Kluskens, L.D., Lavigne, R., Sillankorva, S., Secundo, F., Azeredo, J., Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front. Microbiol., 7, 2016, 208, 10.3389/fmicb.2016.00208.
113. Orito, Y., Morita, M., Hori, K., Unno, H., Tanji, Y., Bacillus amyloliquefaciens phage endolysin can enhance permeability of Pseudomonas aeruginosa outer membrane and induce cell lysis. Appl. Microbiol. Biotechnol. 65 (2004), 105–109, 10.1007/s00253-003-1522-1 https://link.springer.com/article/10.1007/s00253-003-1522-1.
114. Osipovitch, D.C., Therrien, S., Griswold, K.E., Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity. Appl. Microbiol. Biotechnol. 99 (2015), 6315–6326, 10.1007/s00253-015-6443-2.
115. Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J.G., Fischetti, V.A., A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55 (2011), 738–744, 10.1128/AAC.00890-10.
116. Patzer, S.I., Albrecht, R., Braun, V., Zeth, K., Structural and mechanistic studies of pesticin, a bacterial homolog of phage lysozymes. J. Biol. Chem. 287 (2012), 23381–23396, 10.1074/jbc.M112.362913.
117. Paul, V.D., Rajagopalan, S.S., Sundarrajan, S., George, S.E., Asrani, J.Y., Pillai, R., Chikkamadaiah, R., Durgaiah, M., Sriram, B., Padmanabhan, S., A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein. BMC Microbiol., 11, 2011, 226, 10.1186/1471-2180-11-226.
118. Penfold, C.N., Li, C., Zhang, Y., Vankemmelbeke, M., James, R., Colicin A binds to a novel binding site of TolA in the Escherichia coli periplasm. Biochem. Soc. Trans., 40, 2012.
119. Poonacha, N., Nair, S., Desai, S., Tuppad, D., Hiremath, D., Mohan, T., Vipra, A., Sharma, U., Efficient killing of planktonic and biofilm embedded coagulase-negative staphylococci by bactericidal protein P128. Antimicrob. Agents Chemother. 61:8 (2017), e00457–17 AAC.00457-17 https://doi.org/10.1128/AAC.00457-17.
120. Porter, C.J., Schuch, R., Pelzek, A.J., Buckle, A.M., McGowan, S., Wilce, M.C.J., Rossjohn, J., Russell, R., Nelson, D., Fischetti, V.A., Whisstock, J.C., The 1.6 Å crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J. Mol. Biol. 366 (2007), 540–550, 10.1016/j.jmb.2006.11.056.
121. Pritchard, D.G., Dong, S., Kirk, M.C., Cartee, R.T., Baker, J.R., LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae. Appl. Environ. Microbiol. 73 (2007), 7150–7154 http://aem.asm.org/content/73/22/7150.full https://doi.org/10.1128/AEM.01783-07.
122. Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., Yagyu, K., Muraoka, A., Sugai, M., Hiramatsu, K., Honke, K., Matsuzaki, S., Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage φMR11. J. Infect. Dis. 196 (2007), 1237–1247, 10.1086/521305.
123. Raz, A., Serrano, A., Lawson, C., Thaker, M., Alston, T., Bournazos, S., Ravetch, J.V., Fischetti, V.A., Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 4781–4786, 10.1073/pnas.1619249114.
124. Resch, G., Moreillon, P., Fischetti, V.A., A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int. J. Antimicrob. Agents 38 (2011), 516–521, 10.1016/j.ijantimicag.2011.08.009.
125. Resch, G., Moreillon, P., Fischetti, V.A., PEGylating a bacteriophage endolysin inhibits its bactericidal activity. AMB Express, 1, 2011, 29, 10.1186/2191-0855-1-29.
126. Roach, D.R., Donovan, D.M., Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage, 5, 2015, e1062590, 10.1080/21597081.2015.1062590.
127. Rodríguez-Rubio, L., Martínez, B., Rodríguez, A., Donovan, D.M., García, P., Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 HydH5 virion-associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5. Appl. Environ. Microbiol. 78 (2012), 2241–2248, 10.1128/AEM.07621-11.
128. Rodríguez-Rubio, L., Martínez, B., Donovan, D.M., García, P., Rodríguez, A., Potential of the virion-associated peptidoglycan hydrolase HydH5 and its derivative fusion proteins in milk biopreservation. PLoS One, 8, 2013, e54828, 10.1371/journal.pone.0054828.
129. Rodríguez-Rubio, L., Chang, W.-L., Gutiérrez, D., Lavigne, R., Martínez, B., Rodríguez, A., Govers, S.K., Aertsen, A., Hirl, C., Biebl, M., Briers, Y., García, P., “Artilysation” of endolysin λSa2lys strongly improves its enzymatic and antibacterial activity against streptococci. Sci. Rep., 6, 2016, 35382, 10.1038/srep35382 https://www.nature.com/articles/srep35382.
130. Rotolo, J.A., Ramirez, R.A., Schuch, R., Machacek, M., Khariton, T., Ghahramani, P., Wittekind, M., 2016. PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose [WWW Document]. ASM Microbe, June 18.
131. Saravanan, S.R., Paul, V.D., George, S., Sundarrajan, S., Kumar, N., Hebbur, M., Kumar, N., Veena, A., Maheshwari, U., Appaiah, C.B., Chidambaran, M., Bhat, A.G., Hariharan, S., Padmanabhan, S., Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: comparison to recombinant lysostaphin. Bacteriophage, 3, 2013, e26564, 10.4161/bact.26564.
132. Schirmeier, E., Zimmermann, P., Hofmann, V., Biebl, M., Gerstmans, H., Maervoet, V.E., Briers, Y., Inhibitory and bactericidal effect of Artilysin® Art-175 against colistin- resistant mcr-1-positive Escherichia coli isolates. Int. J. Antimicrob. Agents, 2017, 10.1016/j.ijantimicag.2017.08.027.
133. Schmelcher, M., Loessner, M.J., Bacteriophage endolysins: applications for food safety. Curr. Opin. Biotechnol. 37 (2016), 76–87, 10.1016/j.copbio.2015.10.005.
134. Schmelcher, M., Shabarova, T., Eugster, M.R., Eichenseher, F., Tchang, V.S., Banz, M., Loessner, M.J., Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 76 (2010), 5745–5756, 10.1128/AEM.00801-10.
135. Schmelcher, M., Tchang, V.S., Loessner, M.J., Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb. Biotechnol. 4 (2011), 651–662, 10.1111/j.1751-7915.2011.00263.x.
136. Schmelcher, M., Donovan, D.M., Loessner, M.J., Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7 (2012), 1147–1171, 10.2217/fmb.12.97.
137. Schmelcher, M., Powell, A.M., Becker, S.C., Camp, M.J., Donovan, D.M., Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78 (2012), 2297–2305, 10.1128/AEM.07050-11.
138. Schmelcher, M., Powell, A.M., Camp, M.J., Pohl, C.S., Donovan, D.M., Synergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl. Microbiol. Biotechnol. 99 (2015), 8475–8486, 10.1007/s00253-015-6579-0.
139. Schmelcher, M., Shen, Y., Nelson, D.C., Eugster, M.R., Eichenseher, F., Hanke, D.C., Loessner, M.J., Dong, S., Pritchard, D.G., Lee, J.C., Becker, S.C., Foster-Frey, J., Donovan, D.M., Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J. Antimicrob. Chemother. 70 (2015), 1453–1465, 10.1093/jac/dku552.
140. Schuch, R., 2016. Post-antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus in Human Serum [WWW Document]. ASM Microbe, June 20.
141. Schuch, R., Nelson, D., Fischetti, V.A., A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418 (2002), 884–889, 10.1038/nature01026.
142. Shavrina, M.S., Zimin, A.A., Molochkov, N.V., Chernyshov, S.V., Machulin, A.V., Mikoulinskaia, G.V., In vitro study of the antibacterial effect of the bacteriophage T5 thermostable endolysin on Escherichia coli cells. J. Appl. Microbiol. 121 (2016), 1282–1290, 10.1111/jam.13251.
143. Sheehan, M.M., García, J.L., López, R., García, P., Analysis of the catalytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling. FEMS Microbiol. Lett. 140 (1996), 23–28.
144. Sheehan, M.M., García, J.L., López, R., García, P., The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. Mol. Microbiol. 25 (1997), 717–725, 10.1046/j.1365-2958.1997.5101880.x.
145. Shen, Y., Barros, M., Vennemann, T., Gallagher, D.T., Yin, Y., Linden, S.B., Heselpoth, R.D., Spencer, D.J., Donovan, D.M., Moult, J., Fischetti, V.A., Heinrich, F., Lösche, M., Nelson, D.C., A bacteriophage endolysin that eliminates intracellular streptococci. elife, 5, 2016, 10.7554/eLife.13152.
146. Shriber, D.E., Baris, E., Marquez, P. V., Schneidman, M., Jonas, O.B., Berthe, F.C.J., Le Gall, F.G., Nikolic, I.A., Plante, C.A., Irwin, A., Adeyi, O.O., Thiebaud, A., 2017. final report.
147. Singh, A., Arutyunov, D., McDermott, M.T., Szymanski, C.M., Evoy, S., Specific detection of Campylobacter jejuni using the bacteriophage NCTC 12673 receptor binding protein as a probe. Analyst, 136, 2011, 4780, 10.1039/c1an15547d.
148. Singh, A., Arutyunov, D., Szymanski, C.M., Evoy, S., Bacteriophage based probes for pathogen detection. Analyst, 137, 2012, 3405, 10.1039/c2an35371g.
149. Singh, P.K., Donovan, D.M., Kumar, A., Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob. Agents Chemother. 58 (2014), 4621–4629, 10.1128/AAC.00126-14.
150. Skottrup, P.D., Nicolaisen, M., Justesen, A.F., Towards on-site pathogen detection using antibody-based sensors. Biosens. Bioelectron. 24 (2008), 339–348, 10.1016/j.bios.2008.06.045.
151. Sriram, B., Channabasappa, S., Chikkamadaiah, R., Durgaiah, M., Hariharan, S., Jayaraman, R., Kumar, S., Maheshwari, U., Nandish, P., 2017. Pharmacokinetics and efficacy of ectolysin P128 in a mouse model of systemic Methicillin Resistant Staphylococcus aureus (MRSA) infection [WWW Document]. ASM Microbe, June.
152. Sundarrajan, S., Raghupatil, J., Vipra, A., Narasimhaswamy, N., Saravanan, S., Appaiah, C., Poonacha, N., Desai, S., Nair, S., Bhatt, R.N., Roy, P., Chikkamadaiah, R., Durgaiah, M., Sriram, B., Padmanabhan, S., Sharma, U., Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan. Microbiology 160 (2014), 2157–2169, 10.1099/mic.0.079111-0.
153. Taylor, J., Hafner, M., Yerushalmi, E., Smith, R., Bellasio, J., Vardavas, R., Bienkowska-Gibbs, T., Rubin, J., Estimating the Economic Costs of Antimicrobial Resistance. 2014.
154. Thandar, M., Lood, R., Winer, B.Y., Deutsch, D.R., Euler, C.W., Fischetti, V.A., Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant acinetobacter Baumannii. Antimicrob. Agents Chemother. 60 (2016), 2671–2679, 10.1128/AAC.02972-15.
155. Thummeepak, R., Kitti, T., Kunthalert, D., Sitthisak, S., Enhanced antibacterial activity of Acinetobacter baumannii bacteriophage ØABP-01 endolysin (LysABP-01) in combination with colistin. Front. Microbiol., 7, 2016, 1402, 10.3389/fmicb.2016.01402.
156. Tolba, M., Ahmed, M.U., Tlili, C., Eichenseher, F., Loessner, M.J., Zourob, M., A bacteriophage endolysin-based electrochemical impedance biosensor for the rapid detection of Listeria cells. Analyst, 137, 2012, 5749, 10.1039/c2an35988j.
157. Totté, J.E.E., van Doorn, M.B., Pasmans, S.G.M.A., Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin staphefekt SA.100: a report of 3 cases. Case Rep. Dermatol. 9 (2017), 19–25, 10.1159/000473872.
158. Verbree, C.T., Dätwyler, S.M., Meile, S., Eichenseher, F., Donovan, D.M., Loessner, M.J., Schmelcher, M., Identification of peptidoglycan hydrolase constructs with synergistic staphylolytic activity in cow milk. Appl. Environ. Microbiol. 83:7 (2017), e03445–16, 10.1128/AEM.03445-16 (AEM.03445-16).
159. Verbree, C.T., Dätwyler, S.M., Meile, S., Eichenseher, F., Donovan, D.M., Loessner, M.J., Schmelcher, M., Retraction for Verbree et al., “Identification of peptidoglycan hydrolase constructs with synergistic Staphylolytic activity in cow's milk.”. Appl. Environ. Microbiol. 83 (2017), e02100–17, 10.1128/AEM.02100-17.
160. Vipra, A.A., Desai, S.N., Roy, P., Patil, R., Raj, J.M., Narasimhaswamy, N., Paul, V.D., Chikkamadaiah, R., Sriram, B., Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol., 12, 2012, 41, 10.1186/1471-2180-12-41.
161. Walcher, G., Stessl, B., Wagner, M., Eichenseher, F., Loessner, M.J., Hein, I., Evaluation of paramagnetic beads coated with recombinant Listeria phage endolysin–derived cell-wall-binding domain proteins for separation of Listeria monocytogenes from raw milk in combination with culture-based and real-time polymerase cha. Foodborne Pathog. Dis. 7 (2010), 1019–1024, 10.1089/fpd.2009.0475.
162. Walmagh, M., Briers, Y., Santos, S.B. dos, Azeredo, J., Lavigne, R., Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201φ2-1 and PVP-SE1. PLoS One, 7, 2012, e36991, 10.1371/journal.pone.0036991.
163. Walmagh, M., Briers, Y., Santos, S.B. dos, Azeredo, J., Lavigne, R., dos Santos, S.B., Azeredo, J., Lavigne, R., Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201phi2-1 and PVP-SE1. PLoS One, 7, 2012, e36991, 10.1371/journal.pone.0036991.
164. Walmagh, M., Boczkowska, B., Grymonprez, B., Briers, Y., Drulis-Kawa, Z., Lavigne, R., Characterization of five novel endolysins from Gram-negative infecting bacteriophages. Appl. Microbiol. Biotechnol. 97 (2013), 4369–4375, 10.1007/s00253-012-4294-7.
165. Walsh, S., Shah, A., Mond, J., Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 47 (2003), 554–558, 10.1128/aac.47.2.554-558.2003.
166. Wang, S., Gu, J., Lv, M., Guo, Z., Yan, G., Yu, L., Du, C., Feng, X., Han, W., Sun, C., Lei, L., The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region. J. Microbiol. 55 (2017), 403–408, 10.1007/s12275-017-6431-6.
167. WHO, Antimicrobial Resistance: Global Report on Surveillance 2014. 2016, WHO.
168. Wittekind, M., Schuch, R., Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. Curr. Opin. Microbiol. 33 (2016), 18–24, 10.1016/j.mib.2016.05.006.
169. Witzenrath, M., Schmeck, B., Doehn, J.M., Tschernig, T., Zahlten, J., Loeffler, J.M., Zemlin, M., Müller, H., Gutbier, B., Schütte, H., Hippenstiel, S., Fischetti, V.A., Suttorp, N., Rosseau, S., Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit. Care Med. 37 (2009), 642–649, 10.1097/CCM.0b013e31819586a6.
170. Yan, G., Liu, J., Ma, Q., Zhu, R., Guo, Z., Gao, C., Wang, S., Yu, L., Gu, J., Hu, D., Han, W., Du, R., Yang, J., Lei, L., The N-terminal and central domain of colicin A enables phage lysin to lyse Escherichia coli extracellularly. Antonie Van Leeuwenhoek, 2017, 1–9, 10.1007/s10482-017-0912-9.
171. Yang, H., Wang, D.-B., Dong, Q., Zhang, Z., Cui, Z., Deng, J., Yu, J., Zhang, X.-E., Wei, H., Existence of separate domains in lysin PlyG for recognizing Bacillus anthracis spores and vegetative cells. Antimicrob. Agents Chemother. 56 (2012), 5031–5039, 10.1128/AAC.00891-12.
172. Yang, H., Yu, J., Wei, H., Engineered bacteriophage lysins as novel anti-infectives. Front. Microbiol., 5, 2014, 542, 10.3389/fmicb.2014.00542.
173. Yang, H., Zhang, Y., Yu, J., Huang, Y., Zhang, X.-E., Wei, H., Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob. Agents Chemother. 58 (2014), 536–542, 10.1128/AAC.01793-13.
174. Yang, H., Linden, S.B., Wang, J., Yu, J., Nelson, D.C., Wei, H., A chimeolysin with extended-spectrum streptococcal host range found by an induced lysis-based rapid screening method. Sci. Rep., 5, 2015, 17257, 10.1038/srep17257.
175. Yang, H., Wang, M., Yu, J., Wei, H., Antibacterial activity of a novel peptide-modified lysin against Acinetobacter baumannii and Pseudomonas aeruginosa. Front. Microbiol., 6, 2015, 1471, 10.3389/fmicb.2015.01471.
176. Yang, H., Bi, Y., Shang, X., Wang, M., Linden, S.B., Li, Y., Li, Y., Nelson, D.C., Wei, H., Antibiofilm activities of a novel chimeolysin against Streptococcus mutans under physiological and cariogenic conditions. Antimicrob. Agents Chemother. 60 (2016), 7436–7443, 10.1128/AAC.01872-16.
177. Yang, H., Zhang, H., Wang, J., Yu, J., Wei, H., A novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus. Sci. Rep., 7, 2017, 40182, 10.1038/srep40182.
178. Yoong, P., Schuch, R., Nelson, D., Fischetti, V.A., Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J. Bacteriol. 186 (2004), 4808–4812, 10.1128/JB.186.14.4808-4812.2004.
179. Yu, J., Zhang, Y., Zhang, Y., Li, H., Yang, H., Wei, H., Sensitive and rapid detection of staphylococcus aureus in milk via cell binding domain of lysin. Biosens. Bioelectron. 77 (2016), 366–371, 10.1016/j.bios.2015.09.058.
180. Zhang, L., Li, D., Li, X., Hu, L., Cheng, M., Xia, F., Gong, P., Wang, B., Ge, J., Zhang, H., Cai, R., Wang, Y., Sun, C., Feng, X., Lei, L., Han, W., Gu, J., LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Sci. Rep., 6, 2016, 29344, 10.1038/srep29344.
181. Zhou, Y., Zhang, H., Bao, H., Wang, X., Wang, R., The lytic activity of recombinant phage lysin LysKΔamidase against staphylococcal strains associated with bovine and human infections in the Jiangsu province of China. Res. Vet. Sci. 111 (2017), 113–119, 10.1016/j.rvsc.2017.02.011.
182. Zimmer, M., Sattelberger, E., Inman, R.B., Calendar, R., Loessner, M.J., Genome and proteome of Listeria monocytogenes phage PSA: an unusual case for programmed + 1 translational frameshifting in structural protein synthesis. Mol. Microbiol. 50 (2003), 303–317, 10.1046/j.1365-2958.2003.03684.x.